The Mode of Action of Recombinant Mycobacterium tuberculosis Shikimate Kinase: Kinetics and Thermodynamics Analyses

Tuberculosis remains as one of the main cause of mortality worldwide due to a single infectious agent, Mycobacterium tuberculosis. The aroK-encoded M. tuberculosis Shikimate Kinase (MtSK), shown to be essential for survival of bacilli, catalyzes the phosphoryl transfer from ATP to the carbon-3 hydroxyl group of shikimate (SKH), yielding shikimate-3-phosphate and ADP. Here we present purification to homogeneity, and oligomeric state determination of recombinant MtSK. Biochemical and biophysical data suggest that the chemical reaction catalyzed by monomeric MtSK follows a rapid-equilibrium random order of substrate binding, and ordered product release. Isothermal titration calorimetry (ITC) for binding of ligands to MtSK provided thermodynamic signatures of non-covalent interactions to each process. A comparison of steady-state kinetics parameters and equilibrium dissociation constant value determined by ITC showed that ATP binding does not increase the affinity of MtSK for SKH. We suggest that MtSK would more appropriately be described as an aroL-encoded type II shikimate kinase. Our manuscript also gives thermodynamic description of SKH binding to MtSK and data for the number of protons exchanged during this bimolecular interaction. The negative value for the change in constant pressure heat capacity (ΔCp) and molecular homology model building suggest a pronounced contribution of desolvation of non-polar groups upon binary complex formation. Thermodynamic parameters were deconvoluted into hydrophobic and vibrational contributions upon MtSK:SKH binary complex formation. Data for the number of protons exchanged during this bimolecular interaction are interpreted in light of a structural model to try to propose the likely amino acid side chains that are the proton donors to bulk solvent following MtSK:SKH complex formation. © 2013 Rosado et al.

In Vitro and In Vivo Activities of Ruthenium(II) Phosphine/Diimine/Picolinate Complexes (SCAR) against Mycobacterium tuberculosis

Rifampicin, discovered more than 50 years ago, represents the last novel class of antibiotics introduced for the first-line treatment of tuberculosis. Drugs in this class form part of a 6-month regimen that is ineffective against MDR and XDR TB, and incompatible with many antiretroviral drugs. Investments in R&D strategies have increased substantially in the last decades. However, the number of new drugs approved by drug regulatory agencies worldwide does not increase correspondingly. Ruthenium complexes (SCAR) have been tested in our laboratory and showed promising activity against Mycobacterium tuberculosis. These complexes showed up to 150 times higher activity against MTB than its organic molecule without the metal (free ligand), with low cytotoxicity and high selectivity. In this study, promising results inspired us to seek a better understanding of the biological activity of these complexes. The in vitro biological results obtained with the SCAR compounds were extremely promising, comparable to or better than those for first-line drugs and drugs in development. Moreover, SCAR 1 and 4, which presented low acute toxicity, were assessed by Ames test, and results demonstrated absence of mutagenicity. © 2013 Pavan et al.

New isoniazid complexes, promising agents against mycobacterium tuberculosis

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Estrutura cristalográfica da Purina nucleosídeo foslorilase do Mycobacterium tuberculosis

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Estudos estruturais da Purina Nucleosídeo Fosforilase do Mycobacterium tuberculosis complexada com ligantes

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Estudo da influência da infecção pelo Mycobacterium tuberculosis sobre a replicação do HIV e a imunidade celular em associação com os polimorfismos dos genes tlr2 e tlr4

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Determinação dos genótipos para o polimorfismo dos receptores de IgG, FcγRlla (H/R131) e FcγRIIIb (NA1/NA2), e estudo do burst oxidativo dos neutrófilos em indivíduos infectados pelo HIV e/ou Mycobacterium tuberculosis

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Estudo das alterações linfocitárias CD4/CD8 e carga viral em pacientes co-infectados HIV/Mycobacterium tuberculosis associadas a frequência de mutações na região Pol do HIV-1

Pós-graduação em Biociências e Biotecnologia Aplicadas à Farmácia - FCFAR

Atividade anti - Mycobacterium tuberculosis intra e extra celular e citotoxicidade dos complexos de coordenação de metais

Pós-graduação em Biociências e Biotecnologia Aplicadas à Farmácia - FCFAR

Atividade anti - Mycobacterium tuberculosis intra e extracelular e citoxicidade dos complexos de rutênio e vanádio e seus ligantes

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Determinação da atividade anti Mycobacterium tuberculosis de metabólitos bioativos de fungos endofíticos empregando a técnica do MABA

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Genotipagem por Spoligotyping e MIRU de Mycobacterium tuberculosis provenientes de pacientes com tuberculose pulmonar

Pós-graduação em Biociências e Biotecnologia Aplicadas à Farmácia - FCFAR

Estudo estrutural de proteínas alvo de Mycobacterium tuberculosis

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Bioinformática estrutural aplicada ao estudo de proteínas alvo do genoma do Mycobacterium tuberculosis

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Estudo da dinâmica conformacional das enzimas Chiquimato Quinase e 5-enolpiruvilchiquimato-3-Fosfato Sintase (EPSPS) de Mycobacterium tuberculosis através do monitoramento da troca isotópica hidrogênio/deutério por espectrometria de massas ESI

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)